Literature DB >> 18663744

The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.

Chunguang Guo1, Jerome F Sah, Lydia Beard, James K V Willson, Sanford D Markowitz, Kishore Guda.   

Abstract

MicroRNAs (miRNA/miR) are a class of small noncoding RNAs implicated in the pathogenesis of various malignancies. In the current study, using micro(RNA) arrays, we found a ubiquitous loss of miR-126 expression in colon cancer lines when compared to normal human colon epithelia. Reconstitution of miR-126 in colon cancer cells resulted in a significant growth reduction as evidenced in clonogenic assays. A search for miR-126 gene targets revealed p85beta, a regulatory subunit involved in stabilizing and propagating the phosphatidylinositol 3-kinase (PI3K) signal, as one of the potential substrates. Restoration of miR-126 in cancer cells induced a > or =3-fold reduction in p85beta protein levels, with no concomitant change in p85alpha, a gene that is functionally related to p85beta but not a supposed target of miR-126. Additionally, using reporter constructs, we show that the p85beta-3' untranslated region is directly targeted by miR-126. Furthermore, this miR-126 mediated reduction of p85beta was accompanied by a substantial reduction in phosphorylated AKT levels in the cancer cells, suggesting an impairment in PI3K signaling. Finally, in a panel of matched normal colon and primary colon tumors, each of the tumors demonstrated miR-126 down-regulation together with an increase in the p85beta protein level. Taken together, we propose that miR-126 regulates PI3K signaling partly by targeting p85beta, and that the loss of miR-126 may provide a selective growth advantage during colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663744      PMCID: PMC2739997          DOI: 10.1002/gcc.20596

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  21 in total

Review 1.  Signaling by distinct classes of phosphoinositide 3-kinases.

Authors:  B Vanhaesebroeck; M D Waterfield
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

2.  The colorectal microRNAome.

Authors:  Jordan M Cummins; Yiping He; Rebecca J Leary; Ray Pagliarini; Luis A Diaz; Tobias Sjoblom; Omer Barad; Zvi Bentwich; Anna E Szafranska; Emmanuel Labourier; Christopher K Raymond; Brian S Roberts; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

3.  An improved method for staining cell colonies in clonogenic assays.

Authors:  Kishore Guda; Leanna Natale; Sanford D Markowitz
Journal:  Cytotechnology       Date:  2007-06-12       Impact factor: 2.058

4.  Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects.

Authors:  Yogesh Dwivedi; Hooriyah S Rizavi; Tara Teppen; Hui Zhang; Amal Mondal; Rosalinda C Roberts; Robert R Conley; Ghanshyam N Pandey
Journal:  Neuropsychopharmacology       Date:  2007-12-12       Impact factor: 7.853

5.  Silence of chromosomal amplifications in colon cancer.

Authors:  Petra Platzer; Madhvi B Upender; Keith Wilson; Joseph Willis; James Lutterbaugh; Arman Nosrati; James K V Willson; David Mack; Thomas Ried; Sanford Markowitz
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

6.  Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo.

Authors:  Laura S Haneline; Hilary White; Feng-Chun Yang; Shi Chen; Christie Orschell; Reuben Kapur; David A Ingram
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Cell culture of human colon adenomas and carcinomas.

Authors:  J K Willson; G N Bittner; T D Oberley; L F Meisner; J L Weese
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

9.  Endogenous human microRNAs that suppress breast cancer metastasis.

Authors:  Sohail F Tavazoie; Claudio Alarcón; Thordur Oskarsson; David Padua; Qiongqing Wang; Paula D Bos; William L Gerald; Joan Massagué
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  172 in total

1.  Genome-wide screen for miRNA targets using the MISSION target ID library.

Authors:  Matthew J Coussens; Kevin Forbes; Carol Kreader; Jack Sago; Carrie Cupp; John Swarthout
Journal:  J Vis Exp       Date:  2012-04-06       Impact factor: 1.355

2.  MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.

Authors:  Jinhai Li; Yuanyuan Guo; Xiaodi Liang; Ming Sun; Guoliang Wang; Wei De; Wenxi Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-22       Impact factor: 4.553

Review 3.  The interface between phosphatidylinositol transfer protein function and phosphoinositide signaling in higher eukaryotes.

Authors:  Aby Grabon; Vytas A Bankaitis; Mark I McDermott
Journal:  J Lipid Res       Date:  2018-11-30       Impact factor: 5.922

Review 4.  MicroRNAs: key modulators of posttranscriptional gene expression.

Authors:  Steven P O'Hara; Justin L Mott; Patrick L Splinter; Gregory J Gores; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2008-12-03       Impact factor: 22.682

5.  Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Lin Zhong; Mu-Jian Teng; Jun-Wei Fan; Hua-Mei Tang; Jun-Yi Wu; Hong-Yuan Chen; Zhao-Wen Wang; Guo-Qiang Qiu; Zhi-Hai Peng
Journal:  Mol Oncol       Date:  2012-04-17       Impact factor: 6.603

6.  Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4.

Authors:  Zeng Li; Nan Li; Minghua Wu; Xiayu Li; Zhaohui Luo; Xiaoyan Wang
Journal:  Mol Cell Biochem       Date:  2013-06-07       Impact factor: 3.396

Review 7.  How microRNAs influence both hereditary and inflammatory-mediated colon cancers.

Authors:  Jennifer Hutchison; Zoe Cohen; Benjamin C Onyeagucha; Janet Funk; Mark A Nelson
Journal:  Cancer Genet       Date:  2013-09-14

8.  miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.

Authors:  Woori Kim; Yenarae Lee; Noah D McKenna; Ming Yi; Filip Simunovic; Yulei Wang; Benjamin Kong; Robert J Rooney; Hyemyung Seo; Robert M Stephens; Kai C Sonntag
Journal:  Neurobiol Aging       Date:  2014-01-24       Impact factor: 4.673

9.  Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer.

Authors:  Torben Frøstrup Hansen; Claus Lindbjerg Andersen; Boye Schnack Nielsen; Karen-Lise Garm Spindler; Flemming Brandt Sørensen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen
Journal:  Oncol Lett       Date:  2011-08-04       Impact factor: 2.967

Review 10.  AngiomiRs--key regulators of angiogenesis.

Authors:  Shusheng Wang; Eric N Olson
Journal:  Curr Opin Genet Dev       Date:  2009-05-14       Impact factor: 5.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.